Latest News and Press Releases
Want to stay updated on the latest news?
-
Oslo, Norge, 29 september 2004. PhotoCure ASA offentligjør i dag at selskapets søknad om markedsføringstillatelse for Metvix for behandling av aktinisk keratose (AK, forstadier til hudkreft)...
-
Oslo, Norway, 29 September 2004. PhotoCure ASA announces today that its European marketing applications for Metvix, for treatment of actinic keratosis (AK, precancerous skin lesions) and...
-
Oslo, Norway, 23 September 2004 PhotoCure has previously informed that the Swedish regulatory authorities had finished the review for marketing approval for its novel imaging drug Hexvix....
-
Oslo, 23. september 2004 PhotoCure har tidligere medelt at de svenske legemiddelmyndighetene har ferdigstilt vurderingen av det nye legemiddelet Hexvix. I går mottok PhotoCure...
-
Oslo, Norway, 20 September 2004 PhotoCure has today received information from the Swedish regulatory authorities that the review for marketing approval for its novel imaging drug Hexvix is...
-
Oslo, 20. september 2004 PhotoCure har i dag fått melding fra de svenske legemiddelmyndighetene om at vurderingen av det nye legemiddelet Hexvix er avsluttet og formell godkjenning vil...
-
Oslo, Norway, 20 August 2004 Metvix approved in the US PhotoCure ASA (Oslo Stock Exchange: PHO) publishes today its results for the second quarter 2004. Highlights from the report...
-
Oslo 20. august 2004 Metvix godkjent av amerikanske legemiddelmyndigheter PhotoCure ASA (Oslo Børs: PHO) offentliggjør i dag resultatene for 2. kvartal 2004. Høydepunkter fra...
-
Oslo, Norway, 18 August 2004 PhotoCure ASA, Galderma S.A, DUSA Pharmaceuticals Inc. and Queens University at Kingston, announced today that they have entered into a mediation agreement...
-
Oslo, 18. august 2004 DUSA Pharmaceuticals Inc., Queens University i Kingston, Galderma S.A. og PhotoCure ASA kunngjør i dag at partene har undertegnet en avtale om megling for å oppnå en...